CGS 19755

Pricing Availability   Qty
Description: Potent competitive NMDA antagonist
Chemical Name: cis-4-[Phosphomethyl]-piperidine-2-carboxylic acid
Citations (4)
Literature (5)

Biological Activity for CGS 19755

CGS 19755 is a potent, competitive NMDA receptor antagonist. Anticonvulsant and neuroprotective.

Technical Data for CGS 19755

M. Wt 223.17
Formula C7H14NO5P
Storage Store at RT
CAS Number 110347-85-8
PubChem ID 6604838
Smiles O=P(C[C@@H]1C[C@H]([C@](O)=O)NCC1)(O)O

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Solubility Data for CGS 19755

Solvent Max Conc. mg/mL Max Conc. mM
water 5.58 25

Preparing Stock Solutions for CGS 19755

The following data is based on the product molecular weight 223.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.25 mM 17.92 mL 89.62 mL 179.24 mL
1.25 mM 3.58 mL 17.92 mL 35.85 mL
2.5 mM 1.79 mL 8.96 mL 17.92 mL
12.5 mM 0.36 mL 1.79 mL 3.58 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Product Datasheets for CGS 19755

Certificate of Analysis / Product Datasheet
Select another batch:

References for CGS 19755

References are publications that support the biological activity of the product.

Bennett et al (1989) Behavioral pharmacological profile of CGS 19755, a competitive antagonist at N-MthD.-aspartate receptors. J.Pharmacol.Exp.Ther. 250 454 PMID: 2547931

Lehmann et al (1988) CGS 19755, a selective and competitive N-MthD.-aspartate-type excitatory amino acid receptor antagonist. J.Pharmacol.Exp.Ther. 246 65 PMID: 2899170

Perez-Pinzon et al (1995) Correlation of CGS 19755 neuroprotection against in vivo excitotoxicity and focal cerebral ischemia. J.Cereb.Blood Flow Metab. 15 865 PMID: 7673380

If you know of a relevant reference for CGS 19755, please let us know.

View Related Products by Target

View Related Products by Product Action

View all NMDA Receptor Antagonists

Keywords: CGS 19755, CGS 19755 supplier, Potent, competitive, NMDA, antagonists, Glutamate, Receptors, N-Methyl-D-Aspartate, iGlur, Ionotropic, CGS19755, 1241, Tocris Bioscience

4 Citations for CGS 19755

Citations are publications that use Tocris products. Selected citations for CGS 19755 include:

Richardson and Shelton (2015) N-MthD.-aspartate receptor channel blocker-like discriminative stimulus effects of nitrous oxide gas. Cereb Cortex 352 156 PMID: 25368340

Pan et al (2014) Deranged NMDAergic cortico-subthalamic transmission underlies parkinsonian motor deficits. J Pharmacol Exp Ther 124 4629 PMID: 25202982

Pedrazzi et al (2012) Potentiation of NMDA receptor-dependent cell responses by extracellular high mobility group box 1 protein. PLoS One 7 e44518 PMID: 22952988

Jaekel et al (2006) Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons. J Clin Invest 147 622 PMID: 16314856

Do you know of a great paper that uses CGS 19755 from Tocris? Please let us know.

Reviews for CGS 19755

There are currently no reviews for this product. Be the first to review CGS 19755 and earn rewards!

Have you used CGS 19755?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Huntington's Disease Research Product Guide

Huntington's Disease Research Product Guide

This product guide provides a background to Huntington's disease research and lists around 100 products for the study of:

  • Somatic Instability
  • Proteolysis and Inclusion Bodies
  • Transcriptional Dysregulation
  • Mitochondrial Dysfunction
  • Nuclear-Cytoplasmic Transport Interference
  • Excitotoxicity
  • Stem Cells
Alzheimer's Disease Poster

Alzheimer's Disease Poster

Alzheimer's disease (AD) is a debilitating and progressive neurodegenerative disease and the most common cause of dementia, affecting approximately 30% of individuals aged over 85 years. This poster summarizes the cellular and molecular mechanisms of AD.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Huntington's Disease Poster

Huntington's Disease Poster

Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.